ARTICLE | Clinical News
Xerecept corticorelin: Phase I/II data
October 24, 2011 7:00 AM UTC
Data from 15 pediatric patients in the dose-escalation Phase I portion of an open-label, U.S. Phase I/II trial showed that Xerecept led to "substantial" reductions in daily dexamethasone dosing requirements in all patients, with about 25% of patients able to completely stop dexamethasone treatment. The MTD was once-daily 60 µg/kg Xerecept given in divided doses in the morning and evening. The trial enrolled patients who were dependent on chronic dexamethasone dosing due to peritumoral brain edema associated with cerebral tumors. ...